IMS Health’s IDN Impact First to Capture Market Reach, Physician Influence and Brand Dynamics of Integrated Delivery Networks
Brings Together Unique IDN Profiles with Innovative BI Software and Analytics to Drive Local Life Sciences Commercial Execution, Market Growth
DANBURY, Conn.--(BUSINESS WIRE)--IMS Health (NYSE:IMS) today announced the immediate availability in the U.S. of IDN Impact — a first-of-its-kind solution to measure, compare and prioritize the influence of Integrated Delivery Networks (IDNs) on life sciences brands. Combining a unique data set of IDN influence metrics with business intelligence software and local market analysis, IDN Impact enables life sciences organizations to more effectively shape and execute their commercial engagement actions.
“The solution takes into account payer influence within a specific geography while uniquely measuring the impact of an IDN’s activities by therapeutic class and brand — giving our customers deep insights into market dynamics and enabling true brand opportunity segmentation.”
This service for the first time provides visibility into how payers, providers and IDNs drive treatment preferences and protocols within local healthcare markets. Armed with a more complete understanding of these stakeholders and their influence on treatment decisions, commercial leaders can quickly adapt their strategies, align sales and marketing resources, invest more strategically and maximize market share.
“Until now, life sciences companies couldn’t accurately assess the influence of specific IDNs in their local markets or prioritize resources based on measurable results. With a high-degree of precision, IDN Impact delivers a new level of understanding about how these stakeholders affect brand performance,” said Dan Barton, general manager, U.S. Pharmaceutical Solutions, IMS Health. “The solution takes into account payer influence within a specific geography while uniquely measuring the impact of an IDN’s activities by therapeutic class and brand — giving our customers deep insights into market dynamics and enabling true brand opportunity segmentation.”
IDNs bring together groups of hospitals, out-patient facilities and providers to deliver a continuum of care and improve healthcare performance through their distinct policies and practices. In the U.S., more than 80 percent of hospitals are part of an IDN and at least half of physicians are affiliated with one, creating a complex web of local dynamics that affect treatment practices and commercial strategies.
Powered by IMS Health’s unparalleled data resources, technology and consulting expertise, IDN Impact enables commercial teams to measure the influence of IDNs based on factors that include market reach, favorability toward therapeutic classes or brands, and their collective and individual impact on affiliated providers’ prescribing behaviors — all while accounting for local payer and plan influence on treatment decisions.
For more information about IMS Health’s IDN Impact, visit www.imshealth.com.
About IMS Health
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently. Drawing on information from 100,000 suppliers, and on insights from more than 45 billion healthcare transactions processed annually, IMS Health’s approximately 10,000 employees drive results for healthcare clients globally. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at www.imshealth.com.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.